

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Mitra Medical AB	01/14/2008

RECEIVING PARTY DATA

Name:	Biotech IgG AB
Street Address:	Scheelevagen 17
City:	Lund
State/Country:	SWEDEN
Postal Code:	S-223 70

PROPERTY NUMBERS Total: 11

Property Type	Number
Application Number:	09519998
Application Number:	11190955
Application Number:	09750280
Application Number:	11516419
Application Number:	60216635
Application Number:	09881213
Application Number:	10311150
Application Number:	60433012
Application Number:	10538669
Application Number:	60525703
Application Number:	10596012

CORRESPONDENCE DATA

Fax Number: (303)268-0065

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 3032680066

PATENT

500464272

REEL: 020510 FRAME: 0725

CH \$440.00 09519998

Email: tpierce@sbiplaw.com
Correspondent Name: Swanson & Bratschun, LLC
Address Line 1: 8210 SouthPark Terrace
Address Line 4: Littleton, COLORADO 80120

ATTORNEY DOCKET NUMBER:

BIOTECH IGG

NAME OF SUBMITTER:

Margaret M. Wall

Total Attachments: 3

source=Executed Assignment Mitra to Biotech IgG#page1.tif

source=Executed Assignment Mitra to Biotech IgG#page2.tif

source=Executed Assignment Mitra to Biotech IgG#page3.tif


ASSIGNMENT

WHEREAS, the undersigned Mitra Medical AB in bankruptcy, a Swedish corporation with its principal place of business at Ideon Research Park, Lund S-223 70, Sweden and declared bankrupt on the 19th March 2007 by the District Court of Lund, Sweden and thus in the assignment represented by its official receiver ("Assignor") had agreed to transfer and did transfer pursuant to an Acquisition Contract effective June 12, 2007, all of its right, title and interest in the United States and foreign patent rights in each of the inventions described in the patents and patent applications set forth in Appendix A (collectively "Patents"), to Biotech IgG AB (Assignee"), a Swedish corporation with its principal place of business at Scheelevägen 17, S-223 70 Lund, Sweden;

NOW THEREFORE, Assignor, for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, does hereby sell, assign, convey and transfer unto Assignee all right, title and interest in and to the inventions described in said Patents, together with all continuation, divisional, continuation-in-part, reexamination and reissue applications, and all corresponding foreign applications and patents which may be filed thereon, including the right to prosecute such patent applications as well as to claim priority from any application identified in Appendix A. Assignor hereby agrees that Assignor will sign all lawful papers, including, without limitation, all divisional, continuation, continuation-in-part, renewal, extension, reexamination and reissue applications, and make all rightful oaths in execution thereof, and will generally do everything possible to aid Assignee, its successors, assigns and nominees to obtain and enforce proper protection for the inventions, and Patents assigned herein in all countries, this obligation to be binding upon Assignor and upon Assignor's personal representative or other legal successor. This Assignment includes the right, if any, for Assignee to sue or bring other actions for past, present and future infringement. Furthermore, this Assignment shall be deemed a full legal and formal equivalent of any assignment, consent to file or like document which may be required in any country for any purpose regarding the subject matter hereof.

IN TESTIMONY WHEREOF, Assignor has signed below.


Date: 14/1 - 08



Bo Ahlenius
Title: Official Receiver
Mitra Medical AB in bankruptcy

ACCEPTED by Assignee.

Date: 24/01- 2008



Alistair Hurst
Title: CEO
Biotech IgG AB

L:\WPDOCS\Biotech IgG\Mitra Asgt.doc

APPENDIX A

MATTEONO	COUNTRY	SERIALNO	PUBLNO	TITLE	STATUS	FILED
	PCT	PCT/SE98/01345	WO 00/02050	Trifunctional Reagent for Conjugation to a Biomolecule	NATIONAL PHASE	JUL 7 1998
	PCT	PCT/SE99/01241	WO 00/02051	Trifunctional Reagent for Conjugation to a Biomolecule	NATIONAL PHASE	JUL 7 1999
33700.003	US	09/519,998		Reagent for Conjugation to a Biomolecule	ABANDONED	MAR 6 2000
33700.003CON 1	US	11/190,955	US 2005-0271673 A1	Trifunctional Reagent for Conjugation to a Biomolecule	PUBLISHED	JUL 28 2005
33700WC005	US	09/750,280	US 2001-0023288	Trifunctional Reagent for Conjugation to a Biomolecule	PUBLISHED	DEC 29 2000
33700WC005.C ON	US	11/516,419	US-2007-0071673-A1	Trifunctional Reagent for Conjugation to a Biomolecule	PUBLISHED	SEP 6 2006
	US	60/216,635			EXPIRED	JUL 7 2000
	SE	0002287-1			EXPIRED	JUN 16 2000
	PCT	PCT/SE01/01374	WO 01/95857	Biotin derivatives	NATIONAL PHASE	JUN 18 2001
33700WC004	US	09/881,213	US 2002-0159994	Biotin Derivatives	PUBLISHED	JUN 15 2001
033700.006	US	10/311,150	US-2004-0052784	Reusable Extracorporeal Columns Loaded with Ligand-Dibiotin Conjugates	PUBLISHED	APR 23 2003
	US	60/433,012			EXPIRED	DEC 13 2002
	SE	0203731-5			EXPIRED	DEC 13 2002
	PCT	PCT/SE03/01949	WO 04/054615	Antilymphoma Targeting Agents with Affector and Affinity Functions Linked by a Tri-functional Reagent	NATIONAL PHASE	DEC 12 2003
33700.009	US	10/538,669	US 2006-0222588 A1	Antilymphoma Targeting Agents with Effector and Affinity Functions Linked by a Trifunctional Reagent	PUBLISHED	JUN 10 2005
	US	60/525,703			EXPIRED	NOV 28 2003
	SE	0303229-9			EXPIRED	NOV 28 2003
33700.010	US	10/596,012		Targeting of ERB Antigens	PENDING	MAY 25 2006